BLARCAMESINE

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H23NO
Molecular Weight	281.3927
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CC1CCOC1(c2ccccc2)c3ccccc3

InChI

InChIKey=BOTHKNZTGGXFEQ-UHFFFAOYSA-N

InChI=1S/C19H23NO/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,18H,13-15H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C19H23NO
Molecular Weight	281.3927
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.anavex.com/pipeline/anavex-2-73/https://www.ncbi.nlm.nih.gov/pubmed/20829307
Curator's Comment:: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19596910 | https://clinicaltrials.gov/ct2/show/NCT02756858 | https://www.ncbi.nlm.nih.gov/pubmed/19331132 | https://clinicaltrials.gov/ct2/show/NCT02244541 | https://www.ncbi.nlm.nih.gov/pubmed/11976553

AE-37 (ANAVEX2-73, Tetrahydro-N, N-dimethyl-2, 2-diphenyl-3-furanemethanamine) is an orally available drug candidate developed to potentially modify Alzheimer’s disease rather than temporarily address its symptoms. It has a clean Phase 1 data profile and shows a reversal of memory loss (anti-amnesic properties) and neuroprotection in several models of Alzheimer’s disease. This drug is in Phase II trials for Alzheimer's disease, phase I trials for epilepsy, and in preclinical trials for amyotrophic lateral sclerosis, Parkinson's disease, Rett syndrome, stroke. AE-37 may function as a pro-drug for ANAVEX19-144 and acts as a muscarinic receptor and a moderate sigma1 receptor agonist.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor 158 Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20829307	Agonist 2470
Sigma non-opioid intracellular receptor 1 23 Target ID: Q99720\|\|\|Q7Z653 Gene ID: 10280.0 Gene Symbol: SIGMAR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/20829307	Agonist 2470
Sigma opioid receptor 62 Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20829307	Agonist 2470	860.0 nM [IC50]
Glutamate NMDA receptor 41 Target ID: CHEMBL1907608 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20829307	Modulator 780	8.0 µM [IC50]
Sodium channel alpha subunit 69 Target ID: CHEMBL2331043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20829307	Modulator 780	5.1 µM [IC50]
Muscarinic acetylcholine receptor 158 Target ID: CHEMBL2094109 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20829307	Modulator 780

Conditions

Condition	Modality	Highest Phase	Product
Alzheimer’s disease 261 Sources: https://clinicaltrials.gov/ct2/show/NCT02756858	Primary	Phase II 1101	Unknown Approved Use Unknown
Epilepsy 116 Sources: http://adisinsight.springer.com/drugs/800033840	Primary	Phase I 409	Unknown Approved Use Unknown
Rett syndrome 2 Sources: http://adisinsight.springer.com/drugs/800033840	Primary	Phase I 409	Unknown Approved Use Unknown
Epilepsy 116 Sources: http://adisinsight.springer.com/drugs/800033840 http://www.anavex.com/?news=anavex-releases-promising-full-preclinical-epilepsy-data-at-antiepileptic-drug-trials-xiii-conference http://www.anavex.com/?news=anavex-confirms-positive-preclinical-epilepsy-data-for-anavex-2-73-validation-as-potential-platform-drug-for-multiple-neurodegenerative-diseases	Primary	Phase I 409	Unknown Approved Use Unknown
Alzheimer’s disease 261 Sources: http://adisinsight.springer.com/drugs/800033840 http://www.anavex.com/pipeline/ https://www.ncbi.nlm.nih.gov/pubmed/26386305	Primary	Phase II 1101	Unknown Approved Use Unknown
Rett syndrome 2 Sources: http://adisinsight.springer.com/drugs/800033840 http://www.anavex.com/pipeline/	Primary	Phase II 1101	Unknown Approved Use Unknown
Parkinson's disease 219 Sources: http://adisinsight.springer.com/drugs/800033840 http://www.anavex.com/?news=anavex-life-sciences-drug-shows-efficacy-to-support-potential-disease-modification-in-parkinsons-disease	Primary	Preclinical	Unknown Approved Use Unknown
Multiple sclerosis 95 Sources: http://adisinsight.springer.com/drugs/800033840 http://www.anavex.com/?news=anavex-2-73-preclinical-data-in-new-indication-to-be-presented-at-actrims-2016	Primary	Preclinical	Unknown Approved Use Unknown

Doses

Dose	Population	Adverse events
5 mg 1 times / day multiple, intravenous (total daily dose) Highest studied dose Dose: 5 mg, 1 times / day Route: intravenous Route: multiple Dose: 5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32318621/	unhealthy, ADULT Health Status: unhealthy Condition: Alzheimer disease Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/32318621/	Sources: https://pubmed.ncbi.nlm.nih.gov/32318621/
60 mg 1 times / day multiple, oral (unknown) Highest studied dose Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/	healthy, ADULT n = 22 Health Status: healthy Condition: Alzheimer disease Age Group: ADULT Sex: M Food Status: UNKNOWN Population Size: 22 Sources: https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/	Other AEs: Dizziness, headache... Other AEs: Dizziness (moderate) headache (moderate) Sources: https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/
55 mg 1 times / day multiple, oral MTD Dose: 55 mg, 1 times / day Route: oral Route: multiple Dose: 55 mg, 1 times / day Sources: https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/	healthy, ADULT n = 22 Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Population Size: 22 Sources: https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/	Sources: https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/

AEs

AE	Significance	Dose	Population
Dizziness	moderate	60 mg 1 times / day multiple, oral (unknown) Highest studied dose Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/	healthy, ADULT n = 22 Health Status: healthy Condition: Alzheimer disease Age Group: ADULT Sex: M Food Status: UNKNOWN Population Size: 22 Sources: https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/
headache	moderate	60 mg 1 times / day multiple, oral (unknown) Highest studied dose Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/	healthy, ADULT n = 22 Health Status: healthy Condition: Alzheimer disease Age Group: ADULT Sex: M Food Status: UNKNOWN Population Size: 22 Sources: https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/

PubMed

Title	Date	PubMed
[Anticonvulsant and forced swim anti-immobility effects of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanemethanamine (AE37): common action mechanism?].	2002 Mar	11976553
Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative.	2011 Aug	20829307
Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.	2013 Aug	23493042
Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25-35 peptide-injected mice, a nontransgenic Alzheimer's disease model.	2014	25653589
Alzheimer's Association International Conference on Alzheimer's Disease 2015 (AAIC 2015) (July 18-23, 2015 - Washington, D.C., USA).	2015 Jul	26261847
Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments.	2016 Jan 1	26386305

Patents

Sample Use Guides

In Vivo Use Guide

once daily oral (30mg/50mg) and IV (3mg/5mg) administration

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Jun 26 15:32:15 UTC 2021` Edited by `admin` on `Sat Jun 26 15:32:15 UTC 2021`
Record UNII	9T210MMZ3F
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BLARCAMESINE

Official Name

English

ANAVEX 2-73

Code

English

RAC-1-((3R)-2,2-DIPHENYLOXOLAN-3-YL)-N,N-DIMETHYLMETHANAMINE

Systematic Name

English

BLARCAMESINE [INN]

Common Name

English

BLARCAMESINE [USAN]

Common Name

English

3-FURANMETHANAMINE, TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-

Systematic Name

English

TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE

Systematic Name

English

Code System Code Type Description

INN

11031